Table 3. CYP2D6 phenotype and genotype (at baseline) of the 337 healthy subjects and those with over-active bladder disease from 17 Phase 1 studies and the one Phase 2 study on darifenacin used for the pharmacokinetic model.

	Debrisoquine phenotype (n = 129)			Dextromethorphan phenotype (n = 16)
Genotype CYP2D6	EM	PM	Missing	EM	PM	Missing
Homozygote-EM	64	1*	1	11	0	0
Heterozygote-EM	36	2*	0	3	0	0
PM	3*	7	0	0	2	0
Missing	13	2	0	0	0	0

	Unknown phenotype (n = 192)			All phenotype methods (n = 337)
Genotype CYP2D6	EM	PM	Missing	EM	PM	Missing
Homozygote-EM	12	0	88	87	1*	89
Heterozygote-EM	10	0	19	49	2*	19
PM	0	7	9	3*	16	9
Missing	0	0	47	13	2	47

^*Genotype EM classified as phenotype PM or vice versa.